Explore how large-scale, de-identified real-world datasets enable more representative trial design, improve site selection, ...
In today’s ACT Brief, we look at how FDA policy is accelerating the use of de-identified real-world evidence in clinical ...
In today’s ACT Brief, we examine why life sciences companies are maintaining DEI commitments amid political pressure, what’s ...
In today’s ACT Brief, we look at how global clinical development is evolving through decentralized models and emerging ...
In today’s ACT Brief, we look at why durable signal closure is emerging as a defining metric in risk-based quality management ...
In today’s ACT Brief, we look at efforts to address sex-based evidence gaps in Parkinson’s disease research, why ...
Meeting sites where they are—within their systems, workflows, and technology—is something we’re deeply interested in ...
When we think about where AI can help, it’s about reducing administrative burden. Tools like Smart Draft help streamline ...
Pharma is understandably risk-averse, and many companies remain in pilot mode, running small experiments that never scale.
Examine the strategies community research sites can use to secure trial opportunities, from adopting AI-enabled workflows to ...
Mallon: The survey does highlight that principally prolonged contract and budget negotiations are probably the top barriers ...
Unpack why persistent communication breakdowns between sponsors, CROs, and sites undermine startup efficiency—and how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results